| Item type |
文献 / Documents(1) |
| 公開日 |
2023-03-03 |
| アクセス権 |
|
|
アクセス権 |
open access |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 出版社版DOI |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1002/cam4.5145 |
|
|
言語 |
ja |
|
|
関連名称 |
10.1002/cam4.5145 |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| タイトル |
|
|
タイトル |
Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve |
|
言語 |
en |
| 著者 |
友成, 哲
タニ, ジョウジ
佐藤, 康史
田中, 宏典
田中, 貴大
谷口, 達哉
モリシタ, アサヒロ
岡本, 耕一
曽我部, 正弘
宮本, 弘志
六車, 直樹
マサキ, ツトム
高山, 哲治
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Aim: We analyzed the association between the modified albumin–bilirubin (mALBI) grade and therapeutic efficacy of atezolizumab plus bevacizumab (Atezo+Bev) for the treatment of unresectable hepatocellular carcinoma (u-HCC).
Methods: In this retrospective observational study, we included 71 u-HCC patients treated with Atezo+Bev between September 2020 and September 2021. Patients were grouped corresponding to the mALBI grade at the start of treatment (mALBI 1+2a or mALBI 2b+3) and analyzed for therapeutic effect and the transition rate to secondary treatment.
Results: According to the Response Evaluation Criteria in Solid Tumors, the overall response rate was significantly higher for the mALBI 1+2a group, than for the mALBI 2b+3 group, with 26.2% and 3.4%, respectively. The progression-free survival (PFS) was significantly longer in the mALBI 1+2a group (10.5 months) than in the mALBI 2b+3 group (3.0 months). In the multivariate analysis, an mALBI of 1+2a was found to be an independent factor of PFS. The rate of second-line treatment with multi-targeted agents was also significantly higher in the mALBI 1+2a group.
Conclusions: In real-world practice, Atezo+Bev treatment might have higher therapeutic efficacy in u-HCC patients with mALBI 1+2a. |
|
言語 |
en |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
atezolizumab |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
bevacizumab |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
hepatocellular carcinoma |
| 書誌情報 |
en : Cancer Medicine
巻 12,
号 3,
p. 2646-2657,
発行日 2022-08-14
|
| 収録物ID |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
20457634 |
| 出版者 |
|
|
出版者 |
John Wiley & Sons |
|
言語 |
en |
| 権利情報 |
|
|
言語 |
en |
|
権利情報 |
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| EID |
|
|
識別子 |
389441 |
|
識別子タイプ |
URI |
| 言語 |
|
|
言語 |
eng |
cam_12_3_2646.pdf (642 KB)
.png)
